ClinicalTrials.gov record
Completed Phase 2 Interventional

Oral Rigosertib for Squamous Cell Carcinoma

ClinicalTrials.gov ID: NCT01807546

Public ClinicalTrials.gov record NCT01807546. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 11:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma

Study identification

NCT ID
NCT01807546
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Traws Pharma, Inc.
Industry
Enrollment
64 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2013
Primary completion
Feb 28, 2015
Completion
Mar 31, 2016
Last update posted
Jun 25, 2017

2013 – 2016

United States locations

U.S. sites
13
U.S. states
9
U.S. cities
13
Facility City State ZIP Site status
University of California Davis Comprehensive Cancer Center Sacramento California 95817
Stanford Cancer Institute Stanford California 94305
University of Colorado School of Medicine Aurora Colorado 80045
Denver VA Medical Center-ECHCS Denver Colorado 80220
University of Michigan Health System Ann Arbor Michigan 48109
Veterans Administration New Jersey Health Care System East Orange New Jersey 07018
Mount Sinai Medical Center New York New York 10029
Montefiore Medical Center The Bronx New York 10467
Ohio State University, James Cancer Hospital Columbus Ohio 43210
University of Pennslvania Abramson Cancer Center Philadelphia Pennsylvania 19104
Mary Crowley Cancer Research Center Dallas Texas 75201
Virginia Cancer Specialists, PC Fairfax Virginia 22031
Blue Ridge Cancer Care Salem Virginia 24153

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01807546, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 25, 2017 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01807546 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →